Stockholm - Delayed Quote SEK

Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)

Compare
3.5200
+0.0200
+(0.57%)
At close: January 17 at 5:06:30 PM GMT+1

Research Analysis

Revenue vs. Earnings

Revenue 1.5M
Earnings -4.84M
Q4'22
Q1'23
-4M
-2M
0
 

Analyst Price Targets

8.00
8.00 Average
3.5200 Current
8.00 High

Earnings Estimate

Currency in USD Current Qtr. (Nov 2024)Next Qtr. (Feb 2025)Current Year (2025)Next Year (2026)
No. of Analysts ----11
Avg. Estimate 000.20.6
Low Estimate 000.20.6
High Estimate 000.20.6
Year Ago EPS -----0.630.2

Revenue Estimate

Currency in USD Current Qtr. (Nov 2024)Next Qtr. (Feb 2025)Current Year (2025)Next Year (2026)
No. of Analysts ----11
Avg. Estimate ----73.3M141.4M
Low Estimate ----73.3M141.4M
High Estimate ----73.3M141.4M
Year Ago Sales ----36.83M73.3M
Sales Growth (year/est) ----99.03%92.91%

EPS Trend

Currency in USD Current Qtr. (Nov 2024)Next Qtr. (Feb 2025)Current Year (2025)Next Year (2026)
Current Estimate 000.20.6
7 Days Ago 000.20.6
30 Days Ago 000.20.6
60 Days Ago 000.20.6
90 Days Ago 000.20.6

EPS Revisions

Currency in USD Current Qtr. (Nov 2024)Next Qtr. (Feb 2025)Current Year (2025)Next Year (2026)
Up Last 7 Days --------
Up Last 30 Days --------
Down Last 7 Days --------
Down Last 30 Days --------

Growth Estimates

Current Qtr.Next Qtr.Current YearNext Year
NEWBRY.ST ----131.88%200.00%
S&P 500 9.38%11.28%14.02%13.55%